India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)
Executive Summary
2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.You may also be interested in...
Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier
Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.
New Window: India Extends Price Cap Exemption To Foreign Innovation
Innovative medicines developed abroad and patented and launched in India could be entitled to unfettered pricing for a five-year period under new norms announced in the country. Orphan drugs could also qualify for such exemption, much to the concern of healthcare activists.
Lupin Ends 2018 On High, Strikes Large MALT1 Deal With AbbVie
AbbVie has in-licensed Lupin’s MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor program for over $900m in potential milestone payments, bringing Christmas cheer for the Indian firm. The deal terms for the preclinical asset are rather striking.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
